Potential Alzheimer’s Treatments Moving Ahead and Breakthroughs Likely, Scientists Say

Potential Alzheimer’s Treatments Moving Ahead and Breakthroughs Likely, Scientists Say
The Alzheimer’s disease community has grown accustomed to news of an endless string of failures in clinical trials of potential treatments. In fact, only four such treatments went on to win approval between 1998 and 2014 — addressing symptoms but not altering the relentless course of the disease. PhRMA — a group of major U.S. pharmaceutical companies — recently released a list of treatments currently in clinical development for Alzheimer’s, along with a “Medicines in Development 2017 Update” to reassure patients and caregivers that all these failed trials have advanced disease understanding, and that this is reflected in new efforts. But what does this list of more than 80 drugs in testing tell us? Do these trials hold a promise to deliver where others have not? And what exactly have scientists learned from the 123 treatments that failed in clinical studies since 1998? To find out, Alzheimer’s News Today spoke separately to two Alzheimer’s researchers and experts. “We absolutely are working with the highest sense of urgency to try to bring effective therapies to patients. But it is a long road of learning,” said Dr. Matthew Kennedy, director of Early Discovery, Neuroscience, at Merck and a PhRMA representative.  “I'm very excited about what the next few years might bring.” Dr. Dean Hartley, director of scientific initiatives at the Alzheimer's Association, agrees that a breakthrough may
Subscribe or to access all post and page content.

8 comments

  1. Lance Packer says:

    OK. This is all very nice and optimistic and sounds like everything is being done. However, what about the elephant in the room that no one wants to discuss? I’m talking about off-label prescription of already approved drugs which research has shown to have potential for repurposing for Alzheimer’s. From my experience, nobody seems to want to touch that route–neither individual physicians nor institutions. Why? The most obvious conclusion is that there is no money to be made from using out-of-patent or generic drugs. So, no sponsorship of research, etc. It is estimated that 20% of all drug prescriptions to patients generally are made on an off-label basis–except for Alzheimer’s. This is unconscionable and must be changed. As an Alzheimer’s caregiver, I am tired of watching my wife fade away while big Pharma exploits my grief for its monetary gain. Where are the voices of reason and compassion in this tragedy?

  2. Robert Sabin says:

    I am a researcher testing a new AD Drug. It escapes me why Pharma would not want to patent an existing generic for a new use?
    Most of the toxicity work has been completed, just plug the new drug in…

  3. Zachary Yim says:

    Why is intranasal insulin not mentioned? Insulin resistance, hypometabolism of glucose in the brain has been repeatedly mentioned by top-notch research groups in the field in the past as well as most recent publications in 2017 as the cause and an avenue of therapy for AD – especially in view of the failures of amyloid/tau focused approaches. There are ongoing clinical studies on AD, post-stroke cognition impairment, HAND – HIV-associated Neurocognitive Disorder….

  4. David Gregoire says:

    When are we going to see the mentioning of microglia and neuropeptides activation in these discussions? at best, the amyloid antagonists seem to be a wag the dog approach…

  5. The real breakthrough is we have reached a tipping point in Alzheimer’s research. We now know a causal factor of Alzheimer’s is Aluminum accumulation in the brain. We also know dissolved silica facilitates the elimination of Aluminum and stabilizes or improves the cognition of those with Alzheimer’s. Look at Dennis N Crouse’s book Prevent Alzheimer’s, Aluminum and Stroke with 7 Supplements, 7 Lifestyle choices and a Dissolved Mineral. Chapter 1 is available on his website.

    • Chris says:

      There is HopeLaurie, you are so right. I believe that we have reached the tipping point in Alz research because more and more researchers are coming out with clearer results that might eventually break the usual failure gridlock that has plagued Alz research for ages. I am however skeptical that the real workable research info will be surpressed by big Pharma.
      Dennis N Crouse seem to be apt on this and I recommend that people read Prevent Alzheimer’s, Aluminum and Stroke with 7 Supplements…

      Just a hint, I believe lifestyle changes, activity and common-sense remedies are the solution to this disease.

  6. Monique says:

    My husband has early onset Alzheimer’s disease and I’m worried about my children because there’s a fifty percent chance they’ve inherited the disease. I’m most interested in medications that can prevent Alzheimer’s Disease. I’ve read that amyloid is starting to deposit in the brain in the late 20’s of the families that have one of the genetic mutations. I don’t want to watch my children to go through the same illness as my husband but timing is everything to my family!

Leave a Comment

Your email address will not be published. Required fields are marked *